Abstract
Background Inflammation plays a complex, incompletely understood role in the pathogenesis of acute COVID-19 and Post-Acute Sequelae of SARS-CoV-2 infection (PASC or “Long COVID”). Systemic acute inflammation resulting in cytokine storm, hypercoagulability and endothelial damage is thought to be a central mechanism for severe morbidity and mortality in acute COVID-19. Anti-inflammatory medications taken routinely for chronic conditions prior to contracting COVID-19 (“background medications”) may modulate acute COVID-19 outcomes.
Methods Using data from the National COVID Cohort Collaborative (N3C) enclave, we estimated effects of six classes of background medications on acute COVID outcomes. Medication classes included aspirin, celecoxib, other NSAIDS, steroids, immune suppressants, and antidepressants. Acute COVID outcomes included probability of hospital admission, inpatient mortality, and mortality among diagnosed COVID patients. Each medication class was compared to benzodiazepines (excluding midazolam) which served as a comparator/control. Only adult COVID patients with pre-existing osteoarthritis and without any diagnosed autoimmune disease were included in the analyses. Random effects logistic regression models were used to adjust for covariates and data contributing organization. Medication effects also were estimated for COVID-negative cases.
Results Non-aspirin NSAIDS were associated with lower mortality among diagnosed COVID-19 patients: adjusted Odds Ratio (aOR)=0.32 (p=.032) for celecoxib; aOR=0.51 (p<.001) for NSAIDS other than aspirin and celecoxib. For inpatient mortality: aOR=0.34 (p=.060) for celecoxib and aOR=0.74 (p=.200) for other non-aspirin NSAIDS. Similar effects were observed for COVID-negative cases, including for inpatient mortality: aOR=0.21 (p<.001) for celecoxib and aOR=0.34 (p<.001) for other non-aspirin NSAIDS. Secondary analyses examined alternative explanations for results.
Discussion Protective effects were observed for non-aspirin NSAIDS, especially celecoxib. However, those estimated effects implicitly assume the medication classes did not differ on the probability a true COVID-19 case was diagnosed. The similarity of COVID-positive and COVID-negative results suggest possible missing covariates. However, such similarity plausibly could stem from a medication having both “direct” and “indirect” effects on COVID outcomes. Adjudicating among the alternative interpretations would require data beyond those available. However, the effects observed for non-aspirin NSAIDS, while possibly biased, rationalize further investigation using study designs constructed to overcome the limitations of existing datasets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Pennington Biomedical Research Center’s IRB (20211-016-PBRC) and the N3C Data Access Committee (RP-504BA5) approved the study COVID-19 Treatments Associated with Lower Mortality. N3C operates under the authority of the National Institutes of Health IRB, with Johns Hopkins University serving as the central IRB (IRB00249128). No informed consent was obtained from individual patients because the study used a limited data set already stripped of direct identifiers in compliance with the HIPAA Privacy Rule.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵^ Membership of the National COVID Cohort Collaborative Consortium is provided in the Acknowledgments
Data Availability
Data cannot be shared because The N3C Data Enclave is managed under the authority of the NIH information can be found at https://ncats.nih.gov/n3c/resources.
